<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>temozolomide &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/temozolomide/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Fri, 09 Oct 2026 08:47:55 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>temozolomide &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>PARP Inhibitor Plus Temozolomide Shows Promise in Relapsed Small-Cell Lung Cancer Trial</title>
		<link>https://bioengineer.org/parp-inhibitor-plus-temozolomide-shows-promise-in-relapsed-small-cell-lung-cancer-trial/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Fri, 09 Oct 2026 08:47:55 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[biomarkers]]></category>
		<category><![CDATA[BMC Medicine]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[clinical trial]]></category>
		<category><![CDATA[DNA Repair]]></category>
		<category><![CDATA[HTMC0435]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[PARP inhibitor]]></category>
		<category><![CDATA[phase Ib/II]]></category>
		<category><![CDATA[platinum-resistant]]></category>
		<category><![CDATA[small-cell lung cancer]]></category>
		<category><![CDATA[temozolomide]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=409921</guid>

					<description><![CDATA[A phase Ib/II trial in China found that the oral PARP inhibitor HTMC0435 combined with temozolomide produced a manageable safety profile, a 25 percent response rate, and 11.2-month median overall survival in relapsed extensive-stage small-cell lung cancer.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">409921</post-id>	</item>
	</channel>
</rss>
